Stone Point Capital Closes Tenth Flagship Fund with $11.5 Billion of Committed Capital
GREENWICH, Conn. — Stone Point Capital LLC, a private equity firm focused on financial services and related industries, today announced the final closing of its tenth private equity fund, Trident X, with $11.5 billion in total commitments. Trident X exceeded its original target and hard cap of $9 billion and is approximately $2.5 billion larger than Trident IX, a $9 billion fund, which closed in 2022.
Article content
Trident X received strong support from its existing investor base, as well as first-time commitments from a number of leading institutional investors globally. General Partner and affiliated entities contributed approximately $750 million.
'We are grateful to our limited partners for their continued trust and support, and we are proud of the enduring strength of our Trident Funds over 30 years and many market cycles,' said Chuck Davis, Chairman and Co-Chief Executive Officer of Stone Point Capital. 'With Trident X, we will continue doing what we believe we do best – proactively identifying exceptional owner-operators in and around the global financial services industry and helping them build lasting value in their businesses.'
Article content
Jim Carey, Co-Chief Executive Officer of Stone Point Capital, added, 'We believe the consistency of our team, strategy and results continues to give us a distinct advantage in sourcing investments through our extensive network. We are excited by the opportunities we see for our tenth flagship fund and remain focused on creating value for our investors.'
Article content
Trident X began its investment period in May 2025 and has closed on one investment to date – Ultimus Fund Solutions, a provider of full-service fund administration services.
Article content
Stone Point has over 30 years of experience investing in the global financial services industry, beginning with private equity investments in insurance underwriting and expanding over time into a wide range of financial and business services sectors. Members of the senior leadership team have led operations since 1998. The Firm partners with experienced management teams and is flexible with respect to the types of transactions pursued through its Trident Funds. Stone Point has experience in standalone structured buyouts, as well as in carve-outs from larger organizations – bringing deep sector knowledge and an expansive network to every portfolio company engagement. Stone Point has invested in more than 160 companies across 10 active verticals and over 70 sub-sectors. The firm also has a credit-investing platform, Stone Point Credit, which has nearly $10 billion of assets under management.
Article content
Debevoise & Plimpton LLP acted as legal counsel for Stone Point in connection with the formation of Trident X.
Article content
About Stone Point Capital
Article content
Stone Point is an investment firm with more than $65 billion of assets under management across its private equity and credit platforms. Stone Point targets investments in companies in the global financial services industry and related sectors based primarily in North America and Western Europe. The firm invests in alternative asset classes, including private equity through its flagship Trident Funds and credit through commingled funds and separately managed accounts. In addition, Stone Point Capital Markets supports its firm, portfolio companies and other clients by providing dedicated financing solutions. For more information, please visit www.stonepoint.com.
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Media Contacts
Article content
Article content
Prosek Partners
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
25 minutes ago
- CTV News
OpenAI launches US$50 million fund to support nonprofits, community organizations
The OpenAI logo appears on a mobile phone in front of a screen showing part of the company website in this photo taken on Nov. 21, 2023 in New York. (AP Photo/Peter Morgan, File) SAN FRANCISCO — ChatGPT maker OpenAI is launching a US$50 million fund to support nonprofit and community organizations, the artificial intelligence company said on Friday. The fund is the first action following a recommendations report from the San Francisco-based company's nonprofit commission, which was formed in April to guide OpenAI's philanthropic efforts. OpenAI has been working to revamp its corporate structure, which it says is necessary in order to continue raising the massive amounts of capital needed to stay competitive in the AI arms race, a move it is trying to balance with its founding mission, as a nonprofit, to develop AI for the public good. Currently, its nonprofit arm owns and controls its for-profit arm, and OpenAI plans to convert the for-profit entity into a public benefit corporation, of which the nonprofit parent would become a shareholder. The nonprofit commission was established as part of OpenAI's efforts to show that it can remain true to its founding mission despite the corporate revamp. OpenAI said the fund will facilitate partnerships to implement AI in sectors such as education, economic opportunity, community organizing and healthcare. It will also back community-led research and innovation focused on using AI for public good. The nonprofit commission submitted its recommendations report Thursday, following interviews with over 500 nonprofits and community experts. (Reporting by Anna Tong in San Francisco; Editing by Leslie Adler)
CTV News
25 minutes ago
- CTV News
Netflix shares fall as weak U.S. dollar-driven forecast fails to impress
Netflix shares declined more than four per cent on Friday as some investors were disappointed by a revenue forecast that was driven more by a weaker dollar than strong demand for the streamer's content. Expectations were running high for the streaming giant, after its shares nearly doubled in value in the past year and viewers binged on content such as the final season of South Korean survival drama 'Squid Game' in the second quarter. But executives said much of the increase in the annual forecast was driven by weakness in the U.S. dollar, now predicting revenue of between US$44.8 billion and $45.2 billion, up from $43.5 billion to $44.5 billion previously. 'When your shares are already binge-watched to perfection, the earnings beat needed to be stronger to satisfy expectations,' said Michael Ashley Schulman, chief investment officer at Running Point Capital Advisors. 'Instead, some sold on the good news and maybe questioned whether the positive FX effect will be there a few quarters down the road.' A crackdown on password-sharing, more sports content and its ad-supported tier helped Netflix draw tens of millions of new viewers in 2024. But the company stopped reporting subscriber numbers earlier this year, shifting focus to metrics like revenue and profit, a move that has raised concerns about growth. The streaming giant, whose $517-billion market value is more than the combined worth of Disney, Comcast and Warner Bros Discovery, posted quarterly earnings per share of $7.19, beating estimates of $7.08, according to data compiled by LSEG. 'A strong content slate in the second half of the year and growing traction for its advertising efforts could help support continued revenue gains in the third quarter and beyond,' said Seth Shafer, principal analyst at S&P Global Market Intelligence Kagan. At least 16 analysts raised their price targets on the stock following the results, bringing the median target to $1,385, as per data compiled by LSEG. (Reporting by Joel Jose, Siddarth S and Harshita Mary Varghese in Bengaluru; Editing by Leroy Leo)
Globe and Mail
29 minutes ago
- Globe and Mail
Regeneron Stock Plunges 22.6% YTD: Should You Buy, Sell or Hold?
Shares of Regeneron Pharmaceuticals, Inc. REGN have lost 22.6% year to date against the industry 's growth of 0.6%. The stock has underperformed the medical sector and S&P 500 Index in this timeframe. A decline in lead drug Eylea sales has adversely impacted top-line growth. Regeneron Underperforms Industry, Sector and S&P 500 Image Source: Zacks Investment Research While the company is making efforts to diversify its revenue base and develop its oncology franchise, Eylea's dismal performance in an increasingly competitive environment has dampened investors' sentiment. Pipeline setbacks have also hurt the share price of late. Eylea's Sales Decline Hampers REGN Ophthalmology Unit Lead drug Eylea is an anti-vascular endothelial growth factor inhibitor approved for various ophthalmology indications. Eylea sales have boosted the company's top line for many years. However, Eylea's sales have been under pressure in the past couple of years due to competition from Roche 's RHHBY Vabysmo. The uptake of Roche's Vabysmo has been phenomenal. Roche has designed Vabysmo to block pathways involving Ang-2 and VEGF-A. Biosimilar competition for Eylea is also worrisome. Since Eylea accounts for a majority of REGN's sales, a rapid decline in sales has adversely impacted the company's top line. To counter the decline in Eylea sales, Regeneron has developed a higher dose of the drug. While the initial uptake of Eylea HD was encouraging as Eylea patients transitioned to the higher dose, it will take Eylea HD quite some time to offset the rapid erosion in Eylea sales. In April 2025, the FDA accepted for priority review a supplemental biologics license application (sBLA) seeking approval of Eylea HD for both the treatment of macular edema following retinal vein occlusion (RVO) and broadening the dosing schedule to include every 4-week (monthly) dosing across approved indications. The FDA has set a target action date of Aug. 19, 2025. However, the regulatory body issued a complete response letter ('CRL') for the pre-filled syringe of Eylea HD. Per the company, the key outstanding issue relates to a question posed by the FDA to a third-party component supplier. This component supplier has expeditiously responded to FDA requests for information. The FDA also issued a CRL regarding the sBLA for the addition of extended dosing intervals. The FDA indicated that the submitted data did not support extended dosing intervals greater than every 16 weeks. Regeneron has a collaboration agreement with Bayer BAYRY for Eylea. Regeneron records the net product sales of Eylea and Eylea HD in the United States, and Bayer records its net product sales outside the country. Regeneron records its share of profits in connection with Eylea's sales outside the United States. Dupixent Boosts REGN's Top Line REGN's top line also comprises its share of profits/losses in connection with the global sales of Dupixent. Partner Sanofi SNY records global net product sales of Dupixent. Solid sales of Dupixent (approved for use in certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis and eosinophilic esophagitis) have fueled the top line for Sanofi and Regeneron. SNY and REGN are working to expand the drug's label further. The FDA had earlier approved Dupixent for chronic obstructive pulmonary disease (COPD). The approved indication is an add-on maintenance treatment for adults with inadequately controlled COPD and an eosinophilic phenotype. In April 2025, Dupixent's label was further expanded for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria who remain symptomatic despite antihistamine treatment. The FDA recently approved Dupixent for the treatment of adult patients with bullous pemphigoid. Strong demand trends and consistent label expansion should fuel Dupixent sales. REGN's Focus on Oncology The company also has other arrows in its quiver. It is looking to strengthen its oncology franchise, which comprises Libtayo (cemiplimab-rwlc), indicated in certain patients with advanced basal cell carcinoma, advanced cutaneous squamous cell carcinoma and advanced non-small cell lung cancer. REGN's oncology franchise received a boost with the EC's approval of odronextamab for treating adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The drug has been approved under the brand name Ordspono. However, the company's efforts to get odronextamab approved in the United States suffered a setback. The regulatory body issued CRLs for its biologics license application (BLA) for odronextamab in March 2024. The FDA accepted for review the resubmission of the BLA for odronextamab with a target action date of July 30, 2025. Regeneron recently obtained FDA approval of linvoseltamab-gcpt for the treatment of R/R multiple myeloma (MM). The regulatory body granted accelerated approval to linvoseltamab under the brand name Lynozyfic. Lynozyfic is also approved in the European Union to treat adults with R/R MM after at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody. The successful development of these oncology drugs should be a great boost for REGN. REGN Looking to Build an Obesity Franchise Regeneron is looking to make inroads in the lucrative obesity market. The company recently entered into an in-licensing agreement for an obesity drug with Hansoh Pharmaceuticals Group Company Limited, in a bid to expand its clinical-stage obesity portfolio. The licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist. Regeneron will acquire exclusive clinical development and commercial rights for HS-20094, a dual GLP-1/GIP receptor agonist, outside the Chinese Mainland, Hong Kong and Macau. The in-licensing agreement for an obesity candidate will expand REGN's obesity pipeline, which includes trevogrumab. The successful development of any obesity treatment will be a great boost for the company. REGN: Valuation & Estimates Going by the price/earnings ratio, REGN is expensive at this moment. Shares currently trade at 18.27X forward earnings, slightly lower than its mean of 18.85X but higher than the large-cap pharma industry's value of 15.04X. The bottom-line estimate for 2025 has dropped 57 cents to $36.15 over the past 60 days and the same for 2026 has decreased $1.49. Final Thoughts on Regeneron Large biotech companies are considered safe havens for investors interested in this sector. However, Regeneron is sailing in troubled waters as of now and has a tough road ahead, as it will take a long time for Eylea HD to replace Eylea sales. The stock got hammered at the end of May after REGN and partner Sanofi reported mixed results from two late-stage studies, AERIFY-1 and AERIFY-2, on itepekimab for the treatment of chronic obstructive pulmonary disease. While the AERIFY-1 study met the primary endpoint, AERIFY-2 did not meet the same. We believe that the near-term pipeline setbacks and challenges with Eylea weigh on the stock for now. We would advise prospective investors to be on the sidelines for the time being. For investors already owning the stock, selling it at current levels would be prudent. REGN currently carries a Zacks Rank #4 (Sell). You can see . 5 Stocks Set to Double Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include Stock #1: A Disruptive Force with Notable Growth and Resilience Stock #2: Bullish Signs Signaling to Buy the Dip Stock #3: One of the Most Compelling Investments in the Market Stock #4: Leader In a Red-Hot Industry Poised for Growth Stock #5: Modern Omni-Channel Platform Coiled to Spring Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%. Download Atomic Opportunity: Nuclear Energy's Comeback free today. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sanofi (SNY): Free Stock Analysis Report Bayer Aktiengesellschaft (BAYRY): Free Stock Analysis Report
